Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24325888 | 0.86 | KAT2B (0.37) | EPHX1GAABTKSMN1; SMN2CTSS | |
| SCHEMBL24325590 | 0.86 | MAPT (0.40) | EPHX1GAACYP19A1CACNA1BBTK | |
| SCHEMBL25272660 | 0.83 | SCN9A (0.32) | EPHX1GAABTKCTSK | |
| SCHEMBL24325886 | 0.83 | SCN9A (0.32) | EPHX1GAABTKCTSK | |
| SCHEMBL24326572 | 0.82 | KMT2A (0.48) | EPHX1CACNA1BBTKMEN1KMT2A | |
| SCHEMBL25273708 | 0.82 | KMT2A (0.48) | EPHX1CACNA1BBTKMEN1KMT2A | |
| SCHEMBL2252762 | 0.79 | EPHX1 (0.39) | EPHX1GAACYP19A1CACNA1BBTK | |
| SCHEMBL2252759 | 0.79 | EPHX1 (0.39) | EPHX1GAACYP19A1CACNA1BBTK | |
| SCHEMBL4655488 | 0.79 | CACNA1B (0.43) | EPHX1GAACYP19A1CACNA1BBTK | |
| SCHEMBL24325601 | 0.78 | BTK (0.33) | BTKMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9636409-B2 | Enzyme and receptor modulation using covalent conjugates of alpha,alpha-disubstituted glycine esters | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-05-02 | — | — | US | disclosed |
| US-9636409-B2 | Enzyme and receptor modulation using covalent conjugates of alpha,alpha-disubstituted glycine esters | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-05-02 | — | — | US | disclosed |
| US-9636409-B2 | Enzyme and receptor modulation using covalent conjugates of alpha,alpha-disubstituted glycine esters | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-05-02 | — | — | US | disclosed |
| US-20160151509-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20160151509-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20160151509-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-06-02 | — | — | US | disclosed |
| US-8778953-B2 | Inhibitors of P38 map kinase | CHROMA THERAPEUTICS LTD. (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8778953-B2 | Inhibitors of P38 map kinase | CHROMA THERAPEUTICS LTD. (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8778953-B2 | Inhibitors of P38 map kinase | CHROMA THERAPEUTICS LTD. (GB) | 2014-07-15 | — | — | US | disclosed |
| US-20140155439-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-05 | — | — | US | disclosed |
| US-20110046210-A1 | SUBSTITUTED THIOPENECARBOXAMIDES AS IKK-BETA SERINE-, THREONINE-PROTEIN KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20110034520-A1 | Inhibitors of P38 Map Kinase | MACROPHAGE PHARMA LIMITED (GB) | 2011-02-10 | — | — | US | disclosed |
| US-20110034520-A1 | Inhibitors of P38 Map Kinase | MACROPHAGE PHARMA LIMITED (GB) | 2011-02-10 | — | — | US | disclosed |
| US-20110034520-A1 | Inhibitors of P38 Map Kinase | MACROPHAGE PHARMA LIMITED (GB) | 2011-02-10 | — | — | US | disclosed |
| US-20100317865-A1 | ENZYME AND RECEPTOR MODULATION | c/o Chroma Therapeutics Ltd. (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317865-A1 | ENZYME AND RECEPTOR MODULATION | c/o Chroma Therapeutics Ltd. (GB) | 2010-12-16 | — | — | US | disclosed |
| WO-2009141575-A1 | INHIBITORS OF PLK | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009130475-A1 | SUBSTITUTED THIOPHENECARBOXAMIDES AS IKK-BETA SERINE-, THREONINE-PROTEIN KINASE INHIBITORS | CHROMA THERAPEUTICS LTD., (GB) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009106848-A2 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LTD. (GB) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106844-A1 | INHIBITORS OF P38 MAP KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046210-A1 | SUBSTITUTED THIOPENECARBOXAMIDES AS IKK-BETA SERINE-, THREONINE-PROTEIN KINASE INHIBITORS | IKBKE, CSNK1A1, CSNK1E | EPHX1 868/4885GAA 3104/4885CYP19A1 1390/4885 |
| US-20140155439-A1 | ENZYME INHIBITORS | HDAC4, HDAC1, HDAC3 | EPHX1 1882/4885GAA 1520/4885CYP19A1 577/4885 |
| US-20110034520-A1 | Inhibitors of P38 Map Kinase | MAPK3, MAPK1, MAPKAPK3 | EPHX1 656/4885GAA 3189/4885CYP19A1 1233/4885 |
| US-20160151509-A1 | ENZYME AND RECEPTOR MODULATION | CES1, GLRB, GLRA1 | EPHX1 166/4885GAA 121/4885CYP19A1 612/4885 |
| US-20100317865-A1 | ENZYME AND RECEPTOR MODULATION | CES1, GLRB, GLRA1 | EPHX1 166/4885GAA 121/4885CYP19A1 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.